Studies on vaccines, which are seen as a way out of the epidemic in the fight against corona virus worldwide, continue.
In the statement made by the Russian Direct Investments Fund (RDIF), it was reported that the single-dose component of the Sputnik V vaccine developed in the country against the corona virus “Sputnik Light” vaccine was registered for use.
In the statement, “The Russian Ministry of Health, Gamaleya Research Center and RDIF announce that the Sputnik Light corona virus vaccine has been registered. The efficiency level of the vaccine was recorded as 79.4 percent 28 days after the application. The efficiency rate, which is about 80 percent, is higher than the efficiency level of many two-dose vaccines” It was said.
It was stated that the efficacy rate was calculated based on data from Russians who did not receive the second dose of the vaccine for any reason during the mass vaccination program between 5 December 2020 and 15 April 2021.
It was stated that no serious side effects were observed in the volunteers where Sputnik Light was applied, and cellular immunity against the S protein of the virus developed on the 10th day after the application.
‘TO SUPPORT HIGH IMMUNITY IN PREVIOUS INFECTED PEOPLE’
“Sputnik Light will provide support for high immunity in previously infected people,” said Alexander Gintsburg, head of the Gamaleya National Research Center for Epidemiology and Microbiology. Gintsburg also stated that Sputnik Light can be used with different vaccines to be a good tool to increase the level of effectiveness.
Phase III clinical trial of the vaccine, which covers 7 thousand people, continues in many countries, especially in Russia, the United Arab Emirates and Ghana. While temporary results are expected to appear in May, it is aimed to achieve herd immunity faster with a single dose vaccine.